Reversible Cardiomyopathy Associated with Sunitinib and Sorafenib
Authors:
- Imran UraizeeIUImran Uraizee
- Susan ChengSCSusan Cheng
- Javid MoslehiJMJavid Moslehi
- 27 October 2011
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 365 (17) , 1649-1650
Abstract
Tyrosine kinase inhibitors with potent properties against vascular endothelial growth factor (VEGF) signaling pathway (VSP inhibitors) are effective antitumor agents in metastatic renal-cell carcinoma and are now increasingly used in the treatment of other tumors.1 Although VSP inhibitors have been associated with cardiomyopathy, the nature of this side effect is unclear. We report two cases of severe symptomatic, yet reversible, cardiomyopathy after VSP inhibitor therapy.Keywords
This publication has 5 references indexed in Scilit:
- Antiangiogenic therapy: impact on invasion, disease progression, and metastasisNature Reviews Clinical Oncology, 2011
- Cardiomyocyte PDGFR-β signaling is an essential component of the mouse cardiac response to load-induced stressJournal of Clinical Investigation, 2010
- Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumabAmerican Heart Journal, 2009
- Sunitinib‐Induced Cardiotoxicity Is Mediated by Off‐Target Inhibition of AMP‐Activated Protein KinaseClinical and Translational Science, 2009
- Transgenic system for conditional induction and rescue of chronic myocardial hibernation provides insights into genomic programs of hibernationProceedings of the National Academy of Sciences, 2008